Current Issues in Immunisation Against Hepatitis A and B

  • J. N. Zuckerman
  • A. J. Zuckerman


Infection with hepatitis A and hepatitis B viruses is a major public health problem. The development and availability of safe and immunogenic vaccines, which have been shown to be highly effective, constitute a major advance in preventive medicine. Several current issues of practical importance are reviewed below.


Booster Vaccination Intravenous Drug Abuser Major Surface Protein International Reference Preparation HBsAg Mutant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Carman WF, Zanetti AR, Karayiannis P, Water J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC (1990) Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325–329PubMedCrossRefGoogle Scholar
  2. Harrison TJ, Zuckerman AJ (1992) Variants of hepatitis B virus. Vox Sang 63:161–167PubMedCrossRefGoogle Scholar
  3. Lemon SM, Stapleton JT (1997) Prevention of hepatitis A. In: Zuckerman AJ, Thomas HC (eds) Viral hepatitis: scientific basis and clinical management, 2nd edn. Churchill Livingstone, Edinburgh (in press)Google Scholar
  4. McDermott AR, Zuckerman JN, Sabin CA, Marsh SGE, Madrigal JA (1997) The contribution of the human leukocyte antigens in the antibody response to hepatitis B vaccination. Tissue Antigens 50:8–14PubMedCrossRefGoogle Scholar
  5. Oon C-J, Lim G-K, Zhao Y, Goh K-T, Tan K-L, Yo S-L, Hopes E, Harrison TJ, Zuckerman AJ (1995) Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13:699–702PubMedCrossRefGoogle Scholar
  6. Oon C-J, Tan K-L, Harrison T, Zuckerman AJ (1996) Natural history of hepatitis B surface antigen mutants in children. Lancet 348:1524PubMedCrossRefGoogle Scholar
  7. Tedder RS, Zuckerman MA, Brink N (1993) Hepatitis B vaccination: non-responders must be detected. Lancet 307:732Google Scholar
  8. Vandamme P, Thoelen S, Cramm M, de Groote K, Safary A, Meheus A (1994) Inactivated hepatitis A vaccine: reactogenicity, immunogenicity and long-term antibody persistence. J Med Virol 44:446–451CrossRefGoogle Scholar
  9. Vidor E, Fritzell B, Plotkin S (1996) Clinical development of a new inactivated hepatitis A vaccine. Infection 24:447–458PubMedCrossRefGoogle Scholar
  10. Westmoreland D, Player V, Heap DC, Hammond A (1990) Immunization against hepatitis B — what can we expect? Epidemiol Infect 104:499–509PubMedCrossRefGoogle Scholar
  11. WHO (1983) Prevention of liver cancer. WHO Tech Rep Ser 691Google Scholar
  12. Wiedermann G, Ambrosch F, André FE, d’Hondt E, Delem AD, Safary A (1992) Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 10:S129–S131PubMedCrossRefGoogle Scholar
  13. Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, Thomas H, Zuckerman AJ (1988) Hepatitis B variant in Europe. Lancet 2:1132–1133PubMedCrossRefGoogle Scholar
  14. Zuckerman AJ (ed) (1996) Prevention of hepatitis B in the newborn, children and adolescents. Royal College of Physicians, LondonGoogle Scholar
  15. Zuckerman JN (1996) Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 56:283–288CrossRefGoogle Scholar
  16. Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ (1997) Immune response to a new hepatitis B vaccine in health care workers who had not responded to standard vaccine: randomised double blind dose-response study. Br Med J314:329–333CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • J. N. Zuckerman
  • A. J. Zuckerman

There are no affiliations available

Personalised recommendations